Chinese herbal medicine Wutou decoction for knee osteoarthritis

A protocol for systematic review and meta-analysis

Xing Zhou, MM*, Kemeng Xiang, MS, Xiangyao Yuan, MM, Zhenping Wang, MS, Kuanglin Li, MM

Abstract

Background: Knee osteoarthritis (KOA) causes joint pain and limited mobility, which affects the quality of life. The use of Chinese herbal medicine to treat KOA has achieved certain effects, and Wutou decoction (WTD) is one of them. But there is no high-level evidence to support this result. The purpose of this work is to evaluate WTD’s efficacy and safety in the management of KOA.

Methods: We will search articles in 7 electronic databases including Chinese National Knowledge Infrastructure (CNKI), Wanfang Data (WF), Chinese Scientific Journals Database (VIP), Chinese databases Sinomed (CBM), PubMed, Embase, and Cochrane Library databases. All the publications, with no time restrictions, will be searched without any restriction of language and status, the time from the establishment of the database to September 2020. Two reviewers will independently assess the quality of the selected studies, NoteExpress and Excel software will be used to extract data, and the content will be stored in an electronic chart. Different researchers will separately screen the titles and abstracts of records acquired potential eligibility which comes from the electronic databases. Full-text screening and data extraction will be conducted afterward independently. Statistical analysis will be conducted using RevMan 5.4 software.

Results: This study will evaluate the current efficacy and safety of WTD in the treatment of KOA, to provide high-quality, evidence-based clinical recommendations.

Conclusion: This study will provide reliable evidence on whether WTD is safe and effective in treating KOA.

Trial registration number: INPLASY202090022

Abbreviations: KOA = Knee osteoarthritis, RCTs = randomized controlled trials, TCM = Traditional Chinese Medicine, WTD = Wutou decoction.

Keywords: knee osteoarthritis, protocol, randomized controlled trial, systematic review, Wutou decoction

1. Introduction

The number of patients with osteoarthritis worldwide will continue to increase in the coming decades, and it will become one of the most common diseases. Among patients with osteoarthritis, knee joints are the most common, and the prevalence is higher in the middle-aged and elderly population, among which women are higher than men. The reported incidence of knee osteoarthritis (KOA) with radiographic case definition ranges from 7.1% to 70.8%. KOA has caused a huge burden on the patients themselves and the society, accounting for about 85% of the global burden of osteoarthritis. Therefore, there is an urgent thing to seek safe and effective ways to relieve pain and promote the functions of patients, improve the quality of life, and reduce personal and social burdens.

The pathological changes of KOA involve articular cartilage, subchondral bone, synovium, joint capsule, and surrounding muscles and ligaments. KOA is a kind of degenerative disease, which is closely related to aging, but it is not entirely caused by aging, but more of its disease. Because matrix metalloproteinases (MMP) or degradative enzymes are overexpressed in the development of osteoarthritis, the balance is disrupted, resulting in a decrease in the number of proteoglycans, and ultimately causing damage to articular cartilage. Clinically, it is manifested as joint pain and loss of function.

In the management and treatment of KOA, it is mainly divided into surgical intervention and conservative treatment. The first choice of drug therapy in conservative treatment is nonsteroidal anti-inflammatory drugs. The American Academy of Orthopedic Surgeons (AAOS) guidelines have evidence-based medical evidence to support this choice. However, long-term use of...
2. Methods

2.1. Study registration

This protocol report is structured according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis Protocols (PRISMA-P) statement.[23] It is registered on the International Prospective Register of Systematic Reviews. (Registration number INPLASY202090022; https://inplasy.com/inplasy-2020-9-0022/)

2.2. Inclusion criteria

2.2.1. Type of study. Only randomized controlled trials (RCTs) will be included irrespective of blinding, publication status, or language in this study.

2.2.2. Types of participants. Patients were diagnosed with KOA and the study belongs to a RCT. Clinical results included clinical effectiveness and visual analog scale. The experimental group must contain WTD or modified WTD and the control group was not limited except that. Otherwise, studies will be excluded if they cannot meet the inclusion criteria.

2.2.3. Types of interventions. Interventions of the experimental group are WTD or modified WTD. There are no restrictions on the way of administration, dosage, and treatment period.

2.2.4. Types of control groups. The control group has other treatment methods different from WTD or modified WTD.

2.2.5. Outcomes

2.2.5.1. Primary outcome measures. The primary outcome is visual analog scale.[24]

2.2.5.2. Secondary outcomes. The secondary outcomes are clinical effectiveness and the incidence of adverse reactions.

2.3. Search strategy

CNKI, Wanfang, VIP, CBM, PubMed, Embase, and Cochrane Library databases were searched for this study. Take the subject terms combined with free words to search, take PubMed as an example: terms consist of disease (osteoarthritis, knee OR knee osteoarthritis OR knee osteoarthritis OR Osteoarthritis of Knee OR Osteoarthritis of the Knee) and intervention (Wutou decoction OR Wutou Tang OR modified Wutou decoction) and research types (RCT OR controlled clinical trial OR random trials) as shown in Table 1.

2.4. Data collection and analysis

2.4.1. Selection of studies. Different researchers will separately screen the titles and abstracts of records acquired potential eligibility which comes from the electronic databases. The obtained literature is managed by NoteExpress, irrelevant and duplicate articles are excluded by reading the title and abstract. Full texts screening and data extraction will be conducted afterward independently, and finally selected according to the inclusion criteria. Any disagreement will be resolved by discussion until consensus is reached or by consulting a third author. Preferred Reporting Items for Systematic Reviews and Meta-analysis Protocols (PRISMA-P) flowchart will be used to show the selection procedure (Fig. 1).

2.4.2. Data extraction and management. NoteExpress and Excel software will be used to extract data, and the content will be stored in an electronic chart. The following data will be extracted: author, year of publication, country, interventions of experimental groups and control groups, time point, outcome measures, age of patients, the total number of people included in the study, patients’ basic information, etc. Different researchers will separately extract data. Any disagreement regarding data extraction will be resolved by discussion until consensus is reached or by consulting a third author.

2.5. Risk of bias assessment

Two reviewers will independently assess the quality of the selected studies according to the Cochrane Collaboration’s tool.
2.6. Statistical analysis

Statistical analysis will be conducted using RevMan 5.4 software. For continuous data, the mean difference will be used as the effect indicator with 95% confidence interval, and dichotomous data will be calculated as risk ratio or odds ratio as the effect index with 95% confidence interval. The $I^2$ statistic will be used to assess the level of heterogeneity in meta-analysis. When $I^2 < 50\%$, the fixed-effect model can be used for analysis; otherwise, the random-effect model will be used.

2.7. Sensitivity analysis

Through sensitivity analysis, assess the source of heterogeneity by excluding low-quality studies or by excluding one of the included studies in turn. If there is no significant change in the heterogeneity, the results are robust; otherwise, the excluded study may be the heterogeneous origin.

2.8. Subgroup analysis

We will consider the subgroup analysis intervention of the experimental group.

2.9. Publication bias

In this study, less than ten RCTs will use funnel plots to evaluate publication bias, or else, Egger regression test will be used.

3. Discussion

TCM has accumulated a lot of experience in the treatment of joint pain and arthritis. The use of Chinese herbal medicine to treat
KOA has also achieved good results. WTD has a good anti-inflammatory effect, which can relieve knee joint pain, and its curative effect has been confirmed clinically. However, there is still a lack of higher-level evidence-based medicine evidence to support this choice. Therefore, this study is to provide a more credible basis for future clinicians to make decisions. This study still has certain shortcomings, because some factors will lead to biased results, such as low-quality original research, the intervention period, etc, which will weaken the reliability of the evidence.

Author contributions
Conceptualization: Zhou Xing, Xiang Kemeng.
Data curation: Zhou Xing, Xiang Kemeng, Yuan Xiangyao, Wang Zhenping, Li Kuanglin.
Formal analysis: Yuan Xiangyao, Li Kuanglin.
Investigation: Wang Zhenping, Li Kuanglin.
Methodology: Zhou Xing, Xiang Kemeng, Li Kuanglin.
Software: Xiang Kemeng, Wang Zhenping.
Supervision: Yuan Xiangyao, Wang Zhenping, Li Kuanglin.
Writing – original draft: Zhou Xing, Xiang Kemeng.
Writing – review & editing: Yuan Xiangyao, Wang Zhenping.

References
[1] Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. Lancet 2019;393:1745–59.
[2] Prieto-Alhambra D, Judge A, Javaid MK, et al. Incidence and risk factors for clinically diagnosed knee, hip and hand osteoarthritis: influences of age, gender and osteoarthritis affecting other joints. Ann Rheum Dis 2014;73:1659–64.
[3] Turkiewicz A, Petersson IF, Bjork J, et al. Current and future impact of osteoarthritis on health care: a population-based study with projections to year 2032. Osteoarthr Cartil 2014;22:1826–32.
[4] Cvijetic S, Campbell L, Cooper C, et al. Radiographic osteoarthritis in the elderly population of Zagreb: distribution, correlates, and the pattern of joint involvement. Croat Med J 2000;41:58e63.
[5] Oka H, Akune T, Muraki S, et al. Association of low dietary vitamin K intake with radiographic knee osteoarthritis in the Japanese elderly population: dietary survey in a population-based cohort of the ROAD study. J Orthop Sci 2009;14:687e92.
[6] Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016;388:1545–602.
[7] Brandt KD, Radin EL, Dieppe PA, et al. Yet more evidence that osteoarthritis is not a cartilage disease. Ann Rheum Dis 2006;65:1261–4.
[8] Martel-Pelletier J, Barr AJ, Cicuttini FM, et al. Osteoarthritis. Nat Rev Dis Primers 2016;2:16072.
[9] Hsu H, Swieec RM. Knee osteoarthritis. In: StatPears. Treasure Island, FL: StatPears Publishing; 2020.
[10] Kisand K, Tamm AE, Lintrop M, et al. New insights into the natural course of knee osteoarthritis: early regulation of cytokines and growth factors, with emphasis on sex-dependent angiogenesis and tissue remodeling. A Pilot Study. Osteoarthr Cartil 2018;26:1045–54.
[11] Sen R, Hurley JA. Osteoarthritis. In: StatPears. Treasure Island, FL: StatPears Publishing; 2020.
[12] Nelson AE, Allen KD, Golightly YM, et al. A systematic review of recommendations and guidelines for the management of osteoarthritis: the chronic osteoarthritis management initiative of the US bone and joint initiative. Semin Arthritis Rheum 2014;43:701–12.
[13] Awed O, Haider Z, Saeed A, et al. Treatment modalities for hip and knee osteoarthritis: a systematic review of safety. J Orthop Surg (Hong Kong) 2018;26:23094997018808669.
[14] Chen WH, Liu XX, Tong PJ, et al. Orthopaedic Professional Committee, Chinese Association of Research and Advancement of Chinese Traditional Medicine, China; Joint Professional Committee, Branch of Orthopaedic of Chinese Association of Integrative Medicine, China-Diagnosis and management of knee osteoarthritis: Chinese medicine expert consensus (2015). Chin J Integr Med 2016;22:150–3.
[15] Si T, Ma Y, Guo Y, et al. Efficacy and safety of Shaoyang Xibi decoction in patients with knee osteoarthritis: a multi-center, single-blind, randomized controlled trial. J Tradit Chin Med 2018;38:733–9.
[16] Wang X, Cao Y, Pang J, et al. Traditional Chinese Herbal patch for short-term management of knee osteoarthritis: a randomized, double-blind, placebo-controlled trial. Evid Based Complement Alternat Med 2012;2012:171706.
[17] Xu YP, Xie XM, Wang WY. Meta-analysis on efficacy and safety of external use of traditional Chinese medicines and western medicines in treating knee osteoarthritis. Zhongguo Zhong Yao Za Zhi 2012;37:2977–84.
[18] Zhang Y, Wang D, Tan S, et al. A systems biology-based investigation into the pharmacomechanical mechanisms of wu tou tang acting on rheumatoid arthritis by integrating network analysis. Evid Based Complement Alternat Med 2013;2013:548498.
[19] Xu T, Li S, Sun Y, et al. Systematically characterize the absorbed effective substances of Wutou Decoction and their metabolic pathways in rat plasma using UHPLC-Q-TOF-MS combined with a target network pharmacological analysis. J Pharm Biomed Anal 2017;141:95–107.
[20] Dai PM, Wang Y, Ye I, et al. Pharmacokinetic comparisons of benzoyl metacene in rats using ultra-performance liquid chromatography-tandem mass spectrometry after administration of pure benzoyl metacene and Wutou decoction. Molecules 2014;19:1657−69.
[21] Liu YF, Wen CY, Chen Z, et al. Effects of Wutou decoction on DNA methylation and histone modifications in rats with collagen-induced arthritis. Evid Based Complement Alternat Med 2016;2016:3836879.
[22] Luo D, Liang XZ, Liu JB. Network pharmacology study on the mechanism of Wutou decoction in the treatment of osteoarthritis. Chin Pharm 2019;30:2632–8.
[23] Stewart LA, Clarke M, Rovers M, et al. Preferred reporting items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD statement. JAMA 2015;313:1657−65.
[24] Faux KW. VAS–visual analog scale [VAS–visual analog scale]. Tidsskr Nor Laegeforen 2014;134:323.
[25] Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.